Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024523 (malabsorption)
 7,319 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The absorption of D-glucose and brush border membrane disaccharidases in the intestine of rat during infection by Giardia lamblia has been studied. The level of mRNA encoding Na+/glucose co-transporter (SGLT1) and brush border sucrase and lactase activities were also analyzed. At the peak of infection, i.e, day 7, 11 and 15 post-infection, there was a marked decrease in the signal of 4.5 kb and 2.8 kb mRNAs encoding SGTL1 compared to the controls. A similar decrease in sucrase and lactase mRNA's (6.5 kb and 6.8 kb respectively) was also observed under these conditions. This corresponds to observed decrease in the rate of Na(+)-dependent D-glucose uptake and low activities of brush border sucrase and lactase under these conditions. There was no change in Na(+)-independent D-glucose uptake in giardia infected rat intestine. These findings suggest that the down regulation of the expression of SGLT1 and brush border sucrase and lactase activities may be responsible for the observed malabsorption in G. lamblia infection.
 ...
PMID:Expression of sodium-glucose co-transporter and brush border disaccharidases in Giardia lamblia infected rat intestine. 2290 89

Giardiasis is a major global cause of water borne diarrheal disease, which contributes greatly to the burden of malnutrition and malabsorption especially in children. There is a great demand for a new effective therapeutic agent against giardiasis that can be used safely during pregnancy, lactation and in infants. In the present study, the therapeutic effect of spiramycin as well as its immunomodulatory mechanism of action in giardiasis had been investigated. 90 Swiss albino mice were used in this study and classified into 3 groups: GI: 40 mice infected with Giardia lamblia cysts, GII: 40 infected mice that received spiramycin treatment in a daily oral dose of 1000 IU/gm body weight for one week starting one week post infection and GIII: 10 control uninfected untreated mice. 20 mice from each infected group were sacrificed 2 weeks post infection (p.i.) and the remaining mice were sacrificed 4 weeks p.i. Mice of the control groups were sacrificed at one time. The antigiardial therapeutic efficacy of spiramycin was assessed 2 and 4 weeks p.i. by counting of Giardia cysts in stool of mice and studying the histopathological changes and disaccharidase activity in small intestine of mice of different groups. Significant reduction in cysts number shedded in stool of treated animals reached 95.73%. The histopathological changes were mild in all infected groups 2 weeks p.i., while 4 weeks p.i. There was also a significant increase in the number of IELs in treated groups denoting the stimulatory effect of spiramycin on lymphocytic proliferation. On studying the disaccharidase activity, there was significant increase in both sucrase and maltase activities in the treated groups as compared with the nontreated groups. The possible immunomodulatory mechanism of action of spiramycin was studied by measuring the local IgA deposition in small intestinal mucosa by PAP technique 4 weeks p.i. The levels of IgA in small intestine were higher in SP-treated group as compared with the non-treated group. The present results suggested that spiramycin has high efficacy as anti-giardial agent possibly by stimulation of local IgA production.
 ...
PMID:IMMUNOTHERAPEUTIC EFFECT OF SPIRAMYCIN IN EXPERIMENTAL GIARDIASIS. 2736 37


<< Previous 1 2 3 4 5